The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $54.78, denoting a +1.2% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 1.16%. Elsewhere, the Dow gained 1.2%, while the tech-heavy Nasdaq added 1.16%. The company's stock has dropped by 5.3% in the past month, falling short of the Medical sector's gain of 4.5% and the S&P 500's gain of 3.48%. The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The co ...

The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock. Wall Street investment banks keep pounding the table on Viking Therapeutics (VKTX -2.27%) and its weight loss drug candidate. Predictions vary, but the average analyst who follows the stock thinks it can rise 98% from recent prices. Investment bank analysts aren't the only folks on Wall Street who think the clinical-stage biopharma has a bright future. In the second quarter, billionaire mone ...

文章核心观点 - Nvidia公司股价在过去5年内上涨2500%,今年预计将上涨118% [1] - Nvidia主导人工智能芯片市场,占有80%的市场份额,业绩持续大幅增长 [1] - 一家生物科技公司在2024年下半年有望超越Nvidia的股价表现 [1] - 这家生物科技公司是Viking Therapeutics,正在开发治疗肥胖的药物,该市场预计到2030年将达到1000亿美元 [2] 行业和公司研究 肥胖药物市场 - 高盛研究预测,到2030年肥胖药物市场可能达到1000亿美元 [2] - 类似Eli Lilly和Novo Nordisk已上市的药物,通过作用于消化过程中的激素来控制血糖和食欲,受到广泛欢迎 [2] Viking Therapeutics - 正在开发双重GIP/GLP-1受体激动剂类型的候选药物 [2] - 其注射剂VK2735在II期临床试验中达到主要和全部次要终点,患者体重最多减少15% [3] - 口服制剂在I期试验中,患者28天内体重最多减少5.3% [3] - 计划于2024年下半年与FDA进行VK2735的II期临床试验结束会议,并启动III期试验 [3] - 还计划于今年启动口服制剂的II期试验 [3] - 有被大型生物科技或制药公司收购的猜测,这可能推动股价上涨 [4] Nvidia - 即将推出新一代Blackwell架构芯片,这可能推动公司股价上涨 [4] - 但Viking公司在临床试验数据公布后股价单日涨幅超过120%,高于Nvidia在宣布股票拆分后的9%涨幅 [4]

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $58.10, moving -0.5% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.16%. Meanwhile, the Dow gained 0.09%, and the Nasdaq, a tech-heavy index, lost 0.3%. Coming into today, shares of the company had gained 9.49% in the past month. In that same time, the Medical sector gained 4.7%, while the S&P 500 gained 3.64%. The investment community will be paying close attention to the earnings pe ...

Shares of Viking Therapeutics (VKTX) have more than tripled in market value in the past year. The upside was triggered by positive updates on its pipeline programs for obesity and non-alcoholic steatohepatitis (NASH) indications. Based on the encouraging results, management intends to meet with the FDA to discuss the late-stage study design and timings for both programs. In the past year, the stock has significantly outperformed the industry's 2.5% decline. The stock has outperformed the sector and the S&P ...

文章核心观点 - 该公司在生物技术领域拥有很好的临床试验数据,有望在减肥药物市场取得突破 [1][2][3] - 公司有充足的现金储备,足以支持临床试验和产品上市 [3] - 公司还在研究其他代谢类药物,即使减肥药物失败也有其他发展机会 [4] 公司情况总结 - 公司正在开发一种新型减肥药物VK2735,该药物在临床试验中显示出较快的减重速度和良好的安全性 [2][3] - 公司有足够的现金储备,可以支持VK2735的III期临床试验和上市 [3] - 公司还在研究其他代谢类药物,为未来发展提供了多重机会 [4] 行业情况总结 - 目前大型制药公司如Novo Nordisk和Eli Lilly主导着减肥药物市场,但未来可能会被新药物取代 [2] - 制造和供应减肥药物存在一定挑战,需要公司建立合适的生产和合作伙伴关系 [5][6]

文章核心观点 - 制药巨头礼来公司推出了更加便宜的单剂量版本的其热门肥胖药物Zepbound,这将对小型生物科技公司Viking Therapeutics的股价产生负面影响 [1][5][6] - 礼来公司推出这些更便宜的Zepbound版本是为了满足该药物的高需求,同时也可以减少市面上非正规的复制版本 [3][4] - 这一举措可能会给竞争对手诺和诺德公司的肥胖药物Wegovy带来进一步压力 [8][9] - 尽管有大型制药公司的竞争,但小型生物科技公司在肥胖药物市场仍有机会,因为该市场预计到2030年将达到1300亿美元 [11][12] 公司相关 - Viking Therapeutics是一家正在开发GLP-1类肥胖药物VK2735的小型生物科技公司,其股价今年已经上涨了230% [7] - 该公司正在准备将VK2735的皮下注射剂型推进到后期临床,并计划在2024年底前启动口服制剂的中期临床试验 [7] - Viking Therapeutics目前被评为Zacks排名第3(持有)的股票 [13] 行业相关 - 肥胖药物市场巨大,预计到2030年将达到1300亿美元,这说明尽管礼来和诺和诺德已经有了销售数十亿美元的肥胖药,但仍无法满足现有需求 [12] - 除了礼来和诺和诺德,其他制药公司如安进也在开发GLP-1类肥胖药物,预计将在2024年底前获得临床试验数据 [10]

文章核心观点 - 一家大型制药公司Eli Lilly推出了更加便宜的Zepbound减肥药,这可能会对正在开发同类产品的小型生物科技公司Viking Therapeutics造成冲击 [1][2][3][4][5] - Eli Lilly的新产品价格至少便宜50%,这可能会抢占Viking Therapeutics未来的市场份额 [3][4] 行业总结 - GLP-1类减肥药在美国市场非常受欢迎,因为美国有大量超重人群 [6] - 目前市场上批准上市的减肥药很少,Eli Lilly正试图在这一细分市场占据先机 [6] - 如果Viking Therapeutics的减肥药最终上市,将面临来自Eli Lilly的激烈竞争 [5][6]

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX) . Viking Therapeutics currently ...

The new drugs this company is developing could be worth a lot more than the present market value of its stock. Shares of Viking Therapeutics (VKTX 0.43%), a clinical-stage drugmaker working on metabolic treatments, have tripled in value this year. Despite the huge run-up, analysts who follow the company think it has heaps more upside. The average analyst who follows Viking Therapeutics thinks it can rise to $113.55 per share. Reaching the consensus expectation would result in a gain of about 76% from the st ...